 Connection
Kevin Lillehei to Glioma
This is a "connection" page, showing publications Kevin Lillehei has written about Glioma.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.051 |
|
|
|
-
Yang L, Ng KY, Lillehei KO. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control. 2003 Mar-Apr; 10(2):138-47.
Score: 0.168
-
Nevzati E, Chatain GP, Hoffman J, Kleinschmidt-DeMasters BK, Lillehei KO, Ormond DR. Reliability of fluorescein-assisted stereotactic brain biopsies in predicting conclusive tissue diagnosis. Acta Neurochir (Wien). 2020 08; 162(8):1941-1947.
Score: 0.138
-
Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother. 1997 Oct; 45(2):77-87.
Score: 0.115
-
Lillehei KO, Johnson SD, McCleary EL, Mitchell DH, Schiltz PM, Kruse CA. Adjuvant adoptive immunotherapy for pediatric recurrent brain tumors. Online J Curr Clin Trials. 1993 Dec 29; Doc No 111:[806 words; 5 paragraphs].
Score: 0.089
-
Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Bellgrau D, Eule JM, Parra JR, Kong Q, Lillehei KO. Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma. J Neurooncol. 1993 Feb; 15(2):97-112.
Score: 0.084
-
Lillehei KO, Mitchell DH, Johnson SD, McCleary EL, Kruse CA. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery. 1991 Jan; 28(1):16-23.
Score: 0.072
-
Fields EC, Damek D, Gaspar LE, Liu AK, Kavanagh BD, Waziri A, Lillehei K, Chen C. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):51-7.
Score: 0.071
-
Chiocca EA, Smith KM, McKinney B, Palmer CA, Rosenfeld S, Lillehei K, Hamilton A, DeMasters BK, Judy K, Kirn D. A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther. 2008 Mar; 16(3):618-26.
Score: 0.059
-
Schwer AL, Damek DM, Kavanagh BD, Gaspar LE, Lillehei K, Stuhr K, Chen C. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2008 Mar 15; 70(4):993-1001.
Score: 0.058
-
Chang SM, Parney IF, Huang W, Anderson FA, Asher AL, Bernstein M, Lillehei KO, Brem H, Berger MS, Laws ER. Patterns of care for adults with newly diagnosed malignant glioma. JAMA. 2005 Feb 02; 293(5):557-64.
Score: 0.048
-
Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A, Berger MS, Chang S. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003 Sep; 99(3):467-73.
Score: 0.043
-
Chang SM, Parney IF, McDermott M, Barker FG, Schmidt MH, Huang W, Laws ER, Lillehei KO, Bernstein M, Brem H, Sloan AE, Berger M. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg. 2003 Jun; 98(6):1175-81.
Score: 0.043
-
DeMasters BK, Markham N, Lillehei KO, Shroyer KR. Differential telomerase expression in human primary intracranial tumors. Am J Clin Pathol. 1997 May; 107(5):548-54.
Score: 0.028
-
Kruse CA, Lillehei KO, Mitchell DH, Kleinschmidt-DeMasters B, Bellgrau D. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take. Proc Natl Acad Sci U S A. 1990 Dec; 87(24):9577-81.
Score: 0.018
-
Kruse CA, Mitchell DH, Lillehei KO, Johnson SD, McCleary EL, Moore GE, Waldrop S, Mierau GW. Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro. Cancer. 1989 Oct 15; 64(8):1629-37.
Score: 0.017
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|